In silico identification and biological evaluation of a selective MAP4K4 inhibitor against pancreatic cancer

Chao Di Chang, Min Wu Chao, Hsueh Yun Lee, Yi Ting Liu, Huang Ju Tu, Ssu Ting Lien, Tony Eight Lin, Tzu Ying Sung, Shih Chung Yen, Sing Han Huang, Kai Cheng Hsu, Shiow Lin Pan

研究成果: 雜誌貢獻文章同行評審

2 引文 斯高帕斯(Scopus)

摘要

Inhibiting a specific target in cancer cells and reducing unwanted side effects has become a promising strategy in pancreatic cancer treatment. MAP4K4 is associated with pancreatic cancer development and correlates with poor clinical outcomes. By phosphorylating MKK4, proteins associated with cell apoptosis and survival are translated. Therefore, inhibiting MAP4K4 activity in pancreatic tumours is a new therapeutic strategy. Herein, we performed a structure-based virtual screening to identify MAP4K4 inhibitors and discovered the compound F389-0746 with a potent inhibition (IC50 120.7 nM). The results of kinase profiling revealed that F389-0746 was highly selective to MAP4K4 and less likely to cause side effects. Results of in vitro experiments showed that F389-0746 significantly suppressed cancer cell growth and viability. Results of in vivo experiments showed that F389-0746 displayed comparable tumour growth inhibition with the group treated with gemcitabine. These findings suggest that F389-0746 has promising potential to be further developed as a novel pancreatic cancer treatment.
原文英語
文章編號2166039
期刊Journal of Enzyme Inhibition and Medicinal Chemistry
38
發行號1
DOIs
出版狀態已發佈 - 2023

ASJC Scopus subject areas

  • 藥理
  • 藥物發現

指紋

深入研究「In silico identification and biological evaluation of a selective MAP4K4 inhibitor against pancreatic cancer」主題。共同形成了獨特的指紋。

引用此